Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...

Oppenheimer analyst Tyler Batory raised the firm’s price target on Viad (VVI) to $54 from $41 and keeps an Outperform rating on the ...